Staidson Beijing Biopharma (300204) — Tangible Net Worth Ratio
Staidson Beijing Biopharma (300204) has a Tangible Net Worth Ratio of 70.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥236.85 Million) from net assets (CN¥794.92 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300204 total equity for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Staidson Beijing Biopharma Tangible Net Worth Ratio (2007–2025)
This chart shows how Staidson Beijing Biopharma's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 70.2%, reflecting net assets of CN¥794.92 Million with intangible assets of CN¥236.85 Million CNY. Also explore 300204 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Staidson Beijing Biopharma (2007–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Staidson Beijing Biopharma from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see how much is Staidson Beijing Biopharma worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.4% | CN¥806.72 Million | CN¥222.33 Million | CN¥1.27 Billion | ▼ -10.9 pp |
| 2024 | 83.4% | CN¥916.76 Million | CN¥152.34 Million | CN¥1.15 Billion | ▼ -7.1 pp |
| 2023 | 90.4% | CN¥1.02 Billion | CN¥97.62 Million | CN¥1.33 Billion | ▼ -1.6 pp |
| 2022 | 92.1% | CN¥1.35 Billion | CN¥107.22 Million | CN¥1.67 Billion | ▼ -2.3 pp |
| 2021 | 94.4% | CN¥1.55 Billion | CN¥87.34 Million | CN¥1.83 Billion | ▲ +0.9 pp |
| 2020 | 93.5% | CN¥1.59 Billion | CN¥103.10 Million | CN¥1.86 Billion | ▼ -3.4 pp |
| 2019 | 96.9% | CN¥1.64 Billion | CN¥50.34 Million | CN¥1.86 Billion | ▼ -1.3 pp |
| 2018 | 98.2% | CN¥2.46 Billion | CN¥44.70 Million | CN¥2.77 Billion | ▼ -0.2 pp |
| 2017 | 98.3% | CN¥2.21 Billion | CN¥36.47 Million | CN¥2.63 Billion | ▲ +0.3 pp |
| 2016 | 98.1% | CN¥1.92 Billion | CN¥36.93 Million | CN¥2.35 Billion | ▲ +0.3 pp |
| 2015 | 97.8% | CN¥1.68 Billion | CN¥37.39 Million | CN¥2.07 Billion | ▲ +1.9 pp |
| 2014 | 95.9% | CN¥1.51 Billion | CN¥62.17 Million | CN¥1.81 Billion | ▲ +0.7 pp |
| 2013 | 95.2% | CN¥1.31 Billion | CN¥62.61 Million | CN¥1.57 Billion | ▲ +0.4 pp |
| 2012 | 94.9% | CN¥1.24 Billion | CN¥63.65 Million | CN¥1.43 Billion | ▼ -3.0 pp |
| 2011 | 97.9% | CN¥1.10 Billion | CN¥23.52 Million | CN¥1.15 Billion | ▲ +14.1 pp |
| 2010 | 83.7% | CN¥166.23 Million | CN¥27.06 Million | CN¥264.88 Million | ▲ +7.4 pp |
| 2009 | 76.3% | CN¥119.72 Million | CN¥28.34 Million | CN¥148.75 Million | ▲ +26.2 pp |
| 2008 | 50.1% | CN¥62.82 Million | CN¥31.33 Million | CN¥92.07 Million | ▲ +8.8 pp |
| 2007 | 41.4% | CN¥33.87 Million | CN¥19.86 Million | CN¥82.22 Million | — |